New selenium-75 labeled radiopharmaceuticals: selenonium analogues of dopamine.
Selenium-75 labeled selenonium analogues of dopamine, [2-(3,4-dimethoxyphenyl)ethyl]dimethylselenonium iodide (4) and its dihydroxy analogue (7), were prepared by reducing [75Se]selenious acid with sodium borohydride at pH 6.0 and reacting the NaSeH produced with 1-(3,4-dimethoxyphenyl)-2-(p-toluenesulfonyloxy)ethane. Tissue distribution studies in rats given the 75Se-labeled selenonium agents intravenously demonstrated high initial heart uptake (2.38% dose/g at 5 min). Prolonged adrenal retention (t1/2 = 10 h) and high adrenal to blood ratio of compound 4 (21/1 at 4 h after injection) were observed. The high uptake and adrenal to blood ratio suggest the potential use of compound 4 as a radiopharmaceutical for the adrenal gland.
D000311:Adrenal Glands / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000378:metabolism; D004298:Dopamine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism; D005260:Female; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D016566:Organoselenium Compounds; D011868:Radioisotopes; D051381:Rats; D011919:Rats, Inbred Strains; D012643:Selenium / Q000138:chemical synthesis* / Q000378:metabolism; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
D016566:Organoselenium Compounds; D011868:Radioisotopes; C038569:(2-(3,4-dimethoxyphenyl)ethyl)dimethylselenonium; C038570:(2 (3,4-dihydroxyphenyl)ethyl)dimethylselenonium; D012643:Selenium; D004298:Dopamine